Imperial College Healthcare NHS Trust
London, United Kingdom
35 recruiting
Showing 1–20 of 68 trials
Recruiting
Phase 3
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Immune Thrombocytopenic Purpura (ITP)
Takeda150 enrolled108 locationsNCT06948318
Recruiting
Not Applicable
Cryoballoon/Radiofrequency/Pulsed Field Ablation of Atrial Fibrillation Versus Medical Treatment for Heart
Atrial Fibrillation (AF)
University College, London1,200 enrolled24 locationsNCT06505798
Recruiting
Understanding the Variation of Modern Endoscopic Ultrasound Use in Patients With Oesophageal Cancer (VALUE)
Oesophageal Cancer
University Hospital Southampton NHS Foundation Trust160 enrolled14 locationsNCT06440174
Recruiting
Phase 1
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Metastatic Colorectal Cancer
Hoffmann-La Roche542 enrolled76 locationsNCT04929223
Recruiting
BPH Global Registry
Benign Prostatic HyperplasiaLower Urinary Tract Symptoms
Société Internationale d'Urologie7,500 enrolled26 locationsNCT05543200
Recruiting
Not Applicable
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
Refractory Angina
Shockwave Medical, Inc.380 enrolled95 locationsNCT05102019
Recruiting
Using Multiomics to Define Mechanisms of Rhinovirus-induced Chronic Obstructive Pulmonary Disease Exacerbations to Develop Novel Therapies and Therapeutic Targets
COPD, Chronic Obstructive Pulmonary DiseaseExacerbation of COPDRhinovirus Infection
Imperial College London50 enrolled1 locationNCT07112235
Recruiting
Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals975 enrolled216 locationsNCT06541704
Recruiting
Phase 3
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Immune Thrombocytopenic Purpura (ITP)
Takeda171 enrolled112 locationsNCT06722235
Recruiting
Phase 3
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Colorectal Neoplasms
Seagen, a wholly owned subsidiary of Pfizer400 enrolled382 locationsNCT05253651
Recruiting
Phase 4
A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies
Breast Cancer
Hoffmann-La Roche320 enrolled28 locationsNCT06274515
Recruiting
Not Applicable
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
Heart DiseasesCoronary Artery DiseaseCoronary Artery Bypass Grafting
Weill Medical College of Cornell University2,300 enrolled146 locationsNCT04124120
Recruiting
White Matter Distortion and Dementia Biomarkers in Normal Pressure Hydrocephalus (NPH)
Normal Pressure Hydrocephalus
Imperial College London100 enrolled1 locationNCT07103681
Recruiting
Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting
AsthmaVasculitisInflammatory Disease+2 more
Imperial College London120 enrolled1 locationNCT05012033
Recruiting
Cancer Loyalty Card Study 2 (CLOCS-2)
Liver CancerPancreatic CancerOvarian Cancer+7 more
Imperial College London2,900 enrolled1 locationNCT06447064
Recruiting
Phase 3
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
Polycythemia Vera
Italfarmaco220 enrolled90 locationsNCT06093672
Recruiting
Not Applicable
GRACE: Evaluating Compression Stockings in Patients That Require Extended Duration Pharmacological Thromboprophylaxis
SurgeryVenous Thromboembolism
Imperial College London8,608 enrolled3 locationsNCT06166537
Recruiting
Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma
Pancreatic CancerPDAC - Pancreatic Ductal Adenocarcinoma
Imperial College London1,005 enrolled1 locationNCT05727020
Recruiting
Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR2)
Pancreatic CancerPDAC - Pancreatic Ductal Adenocarcinoma
Imperial College London6,079 enrolled1 locationNCT07243262
Recruiting
Phase 2
A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body
Non-Transfusion Dependent Beta-Thalassemia (NTDT)
Regeneron Pharmaceuticals95 enrolled26 locationsNCT06421636